Biomea Fusion Names Hitchcock as Interim CEO, Succeeding Butler

Dow Jones

03-26

By Connor Hart

Biomea Fusion appointed one of its board members, Mick Hitchcock, to succeed Thomas Butler as its interim chief executive.

The change will help to ensure the company realizes its full potential developing a novel therapy for diabetes, it said Tuesday.

Hitchcock has served on the Redwood City, Calif., company's board since March 2021. His career in the pharmaceutical industry began in 1980. He has since held a variety of roles, including leadership positions, at companies including Bristol-Myers Squibb and Gilead Sciences.

As CEO, Hitchcock said he plans to continue the work he has done on Biomea's board. In addition to advancing late stage development efforts and preparing for regulatory engagement regarding Biomea's icovamenib, the company will work to develop its product candidates for the treatment of diabetes.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 25, 2025 19:35 ET (23:35 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2522283777"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522283777\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522283777?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-26 07:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522283777","market":"sg","top_or_hot":-1,"title":"Biomea Fusion Names Hitchcock as Interim CEO, Succeeding Butler","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Biomea Fusion appointed one of its board members, Mick Hitchcock, to succeed Thomas Butler as its interim chief executive. \n</p>\n<p>\n  The change will help to ensure the company realizes its full potential developing a novel therapy for diabetes, it said Tuesday. \n</p>\n<p>\n  Hitchcock has served on the Redwood City, Calif., company's board since March 2021. His career in the pharmaceutical industry began in 1980. He has since held a variety of roles, including leadership positions, at companies including Bristol-Myers Squibb and Gilead Sciences. \n</p>\n<p>\n  As CEO, Hitchcock said he plans to continue the work he has done on Biomea's board. In addition to advancing late stage development efforts and preparing for regulatory engagement regarding Biomea's icovamenib, the company will work to develop its product candidates for the treatment of diabetes. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 19:35 ET (23:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biomea Fusion Names Hitchcock as Interim CEO, Succeeding Butler</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiomea Fusion Names Hitchcock as Interim CEO, Succeeding Butler\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-26 07:35</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Biomea Fusion appointed one of its board members, Mick Hitchcock, to succeed Thomas Butler as its interim chief executive. \n</p>\n<p>\n  The change will help to ensure the company realizes its full potential developing a novel therapy for diabetes, it said Tuesday. \n</p>\n<p>\n  Hitchcock has served on the Redwood City, Calif., company's board since March 2021. His career in the pharmaceutical industry began in 1980. He has since held a variety of roles, including leadership positions, at companies including Bristol-Myers Squibb and Gilead Sciences. \n</p>\n<p>\n  As CEO, Hitchcock said he plans to continue the work he has done on Biomea's board. In addition to advancing late stage development efforts and preparing for regulatory engagement regarding Biomea's icovamenib, the company will work to develop its product candidates for the treatment of diabetes. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 19:35 ET (23:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522283777","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522283777","pubTimestamp":1742945700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Biomea Fusion appointed one of its board members, Mick Hitchcock, to succeed Thomas Butler as its interim chief executive.The change will help to ensure the company realizes its full potential developing a novel therapy for diabetes, it said Tuesday.Hitchcock has served on the Redwood City, Calif., company's board since March 2021. His career in the pharmaceutical industry began in 1980. He has since held a variety of roles, including leadership positions, at companies including Bristol-Myers Squibb and Gilead Sciences.As CEO, Hitchcock said he plans to continue the work he has done on Biomea's board. In addition to advancing late stage development efforts and preparing for regulatory engagement regarding Biomea's icovamenib, the company will work to develop its product candidates for the treatment of diabetes.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4539":"次新股","BMEA":"Biomea Fusion, Inc.","BK4139":"生物科技"},"translate_title":"Biomea Fusion任命希区柯克为临时首席执行官，接替巴特勒","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMEA":1},"content_text":"By Connor Hart \n\n\n \n\n\n  Biomea Fusion appointed one of its board members, Mick Hitchcock, to succeed Thomas Butler as its interim chief executive. \n\n\n  The change will help to ensure the company realizes its full potential developing a novel therapy for diabetes, it said Tuesday. \n\n\n  Hitchcock has served on the Redwood City, Calif., company's board since March 2021. His career in the pharmaceutical industry began in 1980. He has since held a variety of roles, including leadership positions, at companies including Bristol-Myers Squibb and Gilead Sciences. \n\n\n  As CEO, Hitchcock said he plans to continue the work he has done on Biomea's board. In addition to advancing late stage development efforts and preparing for regulatory engagement regarding Biomea's icovamenib, the company will work to develop its product candidates for the treatment of diabetes. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 19:35 ET (23:35 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}